Literature DB >> 4045496

Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type.

J R Atack, E K Perry, R H Perry, I D Wilson, M J Bober, G Blessed, B E Tomlinson.   

Abstract

The major neurochemical abnormality described to date in senile dementia of the Alzheimer type (SDAT) is a central cholinergic deficit. To determine whether this central deficit is reflected by changes in the levels of blood cholinesterases, plasma and erythrocyte acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BChE), were measured in SDAT and other psychiatric disorders. Plasma AChE, which has only recently been described in human blood, was significantly elevated (P less than 0.01) in the SDAT group compared with the control and other clinical groups investigated. In contrast there were no significant differences in the activities of either erythrocyte AChE or plasma BChE between any of the clinical groups. Although the source of plasma AChE is unknown the possibility that some portion originates from the central nervous system and that the elevated AChE levels in SDAT reflect increased release from degenerating cholinergic neurons is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045496     DOI: 10.1016/0022-510x(85)90182-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.

Authors:  K J Reinikainen; P J Riekkinen; L Paljärvi; H Soininen; E L Helkala; J Jolkkonen; M Laakso
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

3.  Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.

Authors:  J Sirviö; R Kutvonen; H Soininen; P Hartikainen; P J Riekkinen
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 4.  Cholinesterases during development of the avian nervous system.

Authors:  P G Layer
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

5.  A search for longitudinal variations in trace element levels in nails of Alzheimer's disease patients.

Authors:  D E Vance; W D Ehmann; W R Markesbery
Journal:  Biol Trace Elem Res       Date:  1990 Jul-Dec       Impact factor: 3.738

6.  Monoclonal antibodies to human brain acetylcholinesterase: properties and applications.

Authors:  Z Rakonczay; S Brimijoin
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

7.  Reassessing blood acetylcholinesterase in dementia.

Authors:  Pengcheng Han
Journal:  J Neurosci Rural Pract       Date:  2015-01

8.  Novel insights on acetylcholinesterase inhibition by Convolvulus pluricaulis, scopolamine and their combination in zebrafish.

Authors:  Kalyani Bindu Karunakaran; Anand Thiyagaraj; Kirankumar Santhakumar
Journal:  Nat Prod Bioprospect       Date:  2022-02-25

9.  Altered levels of acetylcholinesterase in Alzheimer plasma.

Authors:  María-Salud García-Ayllón; Iolanda Riba-Llena; Carol Serra-Basante; Jordi Alom; Rathnam Boopathy; Javier Sáez-Valero
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

10.  Additive toxicity of β-amyloid by a novel bioactive peptide in vitro: possible implications for Alzheimer's disease.

Authors:  Sara Garcia-Ratés; Matthew Lewis; Rosemary Worrall; Susan Greenfield
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.